These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26064512)

  • 21. Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH.
    Bacher R; Hohberg M; Dietlein M; Wild M; Kobe C; Drzezga A; Schmidt M
    J Nucl Med; 2019 May; 60(5):631-637. PubMed ID: 30315143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thyroid hormones and diabetic nephropathy: An essential relationship to recognize.
    Han Q; Zhang J; Wang Y; Li H; Zhang R; Guo R; Li L; Teng G; Wang J; Wang T; Liu F
    Nephrology (Carlton); 2019 Feb; 24(2):160-169. PubMed ID: 29660205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcomes of renal function after radioactive iodine therapy for thyroid cancer according to preparation method: thyroid hormone withdrawal vs. recombinant human thyrotropin.
    Cho YY; Kim SK; Jung JH; Hahm JR; Kim TH; Chung JH; Kim SW
    Endocrine; 2019 May; 64(2):293-298. PubMed ID: 30471053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Assessment of recombinant human thyrotropin application in following-up patients with well-differentiated thyroid carcinoma].
    Rajkovaca Z; Kovacević P; Stanetić M; Ristić S
    Vojnosanit Pregl; 2012 Nov; 69(11):941-6. PubMed ID: 23311243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated serum creatinine level in thyroid cancer patients undergoing withdrawal of thyroxine therapy for radioiodine scan/treatment.
    Hammami MM; Alsaihati B; Alahmari S; Alnuaim AA; Khan BA
    Ann Saudi Med; 1995 Jul; 15(4):358-62. PubMed ID: 17590607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of withdrawal of thyroid hormones versus administration of recombinant human thyroid-stimulating hormone on renal function in thyroid cancer patients.
    An YS; Lee J; Kim HK; Lee SJ; Yoon JK
    Sci Rep; 2023 Jan; 13(1):206. PubMed ID: 36604466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).
    Meier CA; Braverman LE; Ebner SA; Veronikis I; Daniels GH; Ross DS; Deraska DJ; Davies TF; Valentine M; DeGroot LJ
    J Clin Endocrinol Metab; 1994 Jan; 78(1):188-96. PubMed ID: 8288703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated serum creatinine levels in infants with congenital hypothyroidism: reflection of decreased renal function?
    Asami T; Uchiyama M
    Acta Paediatr; 2000 Dec; 89(12):1431-4. PubMed ID: 11195231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of storage of reconstituted recombinant human thyroid-stimulating hormone (rhTSH) on thyroid-stimulating hormone (TSH) response testing in euthyroid dogs.
    De Roover K; Duchateau L; Carmichael N; van Geffen C; Daminet S
    J Vet Intern Med; 2006; 20(4):812-7. PubMed ID: 16955801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Thyrotropin on Peripheral Thyroid Hormone Metabolism and Serum Lipids.
    Beukhof CM; Massolt ET; Visser TJ; Korevaar TIM; Medici M; de Herder WW; Roeters van Lennep JE; Mulder MT; de Rijke YB; Reiners C; Verburg FA; Peeters RP
    Thyroid; 2018 Feb; 28(2):168-174. PubMed ID: 29316865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
    Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
    Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of serum total thyroxine, triiodothyronine, free thyroxine, and thyrotropin concentrations for diagnosis of hypothyroidism in dogs.
    Peterson ME; Melián C; Nichols R
    J Am Vet Med Assoc; 1997 Dec; 211(11):1396-402. PubMed ID: 9394888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations between metabolic syndrome, serum thyrotropin, and thyroid antibodies status in postmenopausal women, and the role of interleukin-6.
    Siemińska L; Wojciechowska C; Walczak K; Borowski A; Marek B; Nowak M; Kajdaniuk D; Foltyn W; Kos-Kudła B
    Endokrynol Pol; 2015; 66(5):394-403. PubMed ID: 26457493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Change in serum thyroid-stimulating hormone concentration in response to administration of thyrotropin-releasing hormone to healthy dogs, hypothyroid dogs, and euthyroid dogs with concurrent disease.
    Scott-Moncrieff JC; Nelson RW
    J Am Vet Med Assoc; 1998 Nov; 213(10):1435-8. PubMed ID: 9828939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between serum TSH levels and intrarenal hemodynamic parameters in euthyroid subjects.
    Tsuda A; Inaba M; Ichii M; Ochi A; Ohno Y; Nakatani S; Yamada S; Mori K; Tahara H; Ishimura E
    Eur J Endocrinol; 2013 Jul; 169(1):45-50. PubMed ID: 23585555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RENAL FUNCTION AND PLASMA RENIN ACTIVITY AS POTENTIAL FACTORS CAUSING HYPERKALEMIA IN PATIENTS WITH THYROID CARCINOMA UNDERGOING THYROID HORMONE WITHDRAWAL FOR RADIOACTIVE IODINE THERAPY.
    Niri T; Horie I; Ando T; Kawahara H; Ueda M; Eto M; Sako A; Ikeuchi Y; Nakao T; Nakashima Y; Shigeno R; Ito A; Nozaki A; Haraguchi A; Natsuda S; Sagara I; Akazawa S; Kamada A; Imaizumi M; Abiru N; Usa T; Kawakami A
    Endocr Pract; 2020 Feb; 26(2):197-206. PubMed ID: 31652100
    [No Abstract]   [Full Text] [Related]  

  • 39. Peripheral metabolism of homologous thyrotropin in euthyroid and hypothyroid rats: acute effects of thyrotropin-releasing hormone, triiodothyronine, and thyroxine.
    Silva JE; Larsen PR
    Endocrinology; 1978 Jun; 102(6):1783-96. PubMed ID: 105884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma.
    Giusti M; Cecoli F; Ghiara C; Rubinacci A; Villa I; Cavallero D; Mazzuoli L; Mussap M; Lanzi R; Minuto F
    Hormones (Athens); 2007; 6(4):304-13. PubMed ID: 18055421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.